TGN signs a CDA with Moffitt Cancer Center

Tampa July 22, 2016.

TransGenex Nanobiotech (TGN) Inc., Tampa FL has signed a confidential disclosure agreement (CDA) with the H. Lee Moffitt Cancer Center and Research Institute Inc., a not-for-profit corporation and NCI-designated Comprehensive Cancer Center located in Tampa, FL.  This CDA will allow discussions and information exchange between the two entities to explore a potential relationship for the benefit of both parties in connection with TGN's FiSS4D Tumoroid culture technology platform, anti-cancer drug discovery and development, and personalized cancer treatments.  TGN has developed FiSS4D, a technology that can grow tumoroids (tumor-like), from patient biopsy samples or surgically discarded cells, under cell culture conditions. Tumoroids closely resemble patient tumors in the body and provide a simple method to determine drug treatment efficacy.  Moffitt Cancer Center has made a lasting commitment to the prevention and cure of cancer, with a vision to transform cancer care service, science and partnership.